CTS East 2025

Dawie’s deep expertise across multiple therapeutic areas, multinational development leadership, and experience in associated commercial growth supports the expanding impact of the Signant Science and Medical team. Dawie joins us from AES, where he served as Chief Medical Officer for five and a half years. Prior to AES, he held various research and senior leadership roles at Parexel for over 15 years, developing and implementing medical scientific focused business strategies across the early phase space. Dawie holds MBA and MBChB MBA (Medicine and Business) degrees from University of the Free State, South Africa. We are rightly proud of our science and medical heritage and how it has contributed to – and continues to – position us as leaders in our industry. Building on the therapeutic approach to our sales pipeline, the development of our offerings across as many therapeutic areas as possible continues under Dawie’s leadership. Originally hailing from South Africa, Dawie is based in the UK.

Dawie’s deep expertise across multiple therapeutic areas, multinational development leadership, and experience in associated commercial growth supports the expanding impact of the Signant Science and Medical team. Dawie joins us from AES, where he served as Chief Medical Officer for five and a half years. Prior to AES, he held various research and senior leadership roles at Parexel for over 15 years, developing and implementing medical scientific focused business strategies across the early phase space. Dawie holds MBA and MBChB MBA (Medicine and Business) degrees from University of the Free State, South Africa. We are rightly proud of our science and medical heritage and how it has contributed to – and continues to – position us as leaders in our industry. Building on the therapeutic approach to our sales pipeline, the development of our offerings across as many therapeutic areas as possible continues under Dawie’s leadership. Originally hailing from South Africa, Dawie is based in the UK.

Ed Pollack serves as Chief Technology Officer where he steers strategy and oversees delivery of the products and systems underpinning Signant’s growth strategy. He is responsible for driving high-performance, cross-functional teams across several disciplines and leading the development and optimization of clinical trial solutions for Signant’s life sciences customers across the globe. 

Ed joins Signant from Elsevier, a leader in helping healthcare professionals advance science and improve patient outcomes, where he served as vice president of technology. His experience there, as well as his extensive background in software engineering, ensure Signant is prepared with the leadership and vision to continue scaling through accelerated growth while delivering industry-leading solutions to customers.  

Prior to Elsevier, Ed held technology leadership roles at several companies focused on supporting the regulatory business process of global life sciences companies. 

Ed holds a Bachelor of Business Administration in Computer Science from Temple University.